Subject:
- Active Substance: Vosoritide
- Name: Voxzogo®
- Therapeutic area: Achondroplasia
- Pharmaceutical company: BioMarin International Limited
Time table:
- Start: 01.10.2021
- Final decision by G-BA: 18.03.2022
Final decision:
- Hint for a non-quantifiable additional benefit (orphan drug)